NasdaqGS:AVRO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. More Details


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has AVROBIO's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AVRO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.8%

AVRO

-3.4%

US Biotechs

-2.4%

US Market


1 Year Return

13.3%

AVRO

35.9%

US Biotechs

18.2%

US Market

Return vs Industry: AVRO underperformed the US Biotechs industry which returned 39.3% over the past year.

Return vs Market: AVRO underperformed the US Market which returned 19.5% over the past year.


Shareholder returns

AVROIndustryMarket
7 Day1.8%-3.4%-2.4%
30 Day0.9%0.7%4.2%
90 Day-15.5%-4.7%6.3%
1 Year13.3%13.3%38.3%35.9%20.9%18.2%
3 Yearn/a18.5%12.5%41.2%31.8%
5 Yearn/a17.2%8.9%84.8%63.9%

Price Volatility Vs. Market

How volatile is AVROBIO's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AVROBIO undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AVRO ($16.14) is trading below our estimate of fair value ($68.78)

Significantly Below Fair Value: AVRO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AVRO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AVRO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AVRO is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is AVROBIO forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

10.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AVRO's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AVRO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AVRO is forecast to be unprofitable in 3 years.


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has AVROBIO performed over the past 5 years?

-51.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVRO is currently unprofitable.

Growing Profit Margin: AVRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVRO is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.

Accelerating Growth: Unable to compare AVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: AVRO has a negative Return on Equity (-39.46%), as it is currently unprofitable.


Next Steps

Financial Health

How is AVROBIO's financial position?


Financial Position Analysis

Short Term Liabilities: AVRO's short term assets ($251.0M) exceed its short term liabilities ($15.4M).

Long Term Liabilities: AVRO's short term assets ($251.0M) exceed its long term liabilities ($370.0K).


Debt to Equity History and Analysis

Debt Level: AVRO is debt free.

Reducing Debt: AVRO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVRO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AVRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is AVROBIO current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Geoff MacKay (54 yo)

4.92yrs

Tenure

US$1,816,378

Compensation

Mr. Geoff MacKay, BSc, serves as Chief Executive Officer and President of AVROBIO Inc. Mr. MacKay served as Interim Chief Executive Officer at Egenesis Inc. Mr. MacKay is an Atlas Advisor at Atlas Venture ...


CEO Compensation Analysis

Compensation vs Market: Geoff's total compensation ($USD1.82M) is about average for companies of similar size in the US market ($USD1.91M).

Compensation vs Earnings: Geoff's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Geoff MacKay
Co- Founder4.92yrsUS$1.82m1.35%
$ 7.9m
Erik Ostrowski
CFO & Treasurer1.75yrsUS$2.75m0.0020%
$ 11.6k
Steven Avruch
Chief Legal Officer & Secretary1.75yrsUS$1.38m0%
$ 0
Jeffrey Medin
Scientific Founderno datano datano data
Matthew Arnold
Head of Operations0.75yrno datano data
Kim Raineri
Chief Manufacturing & Technology Officer0.33yrno datano data
Chris Mason
Chief Scientific Officerno datano datano data
Monique Da Silva
Senior Vice President of Corporate Communications0.75yrno datano data
Georgette Verdin
Chief Human Resources Officer1.17yrsno datano data
Deanna Petersen
Chief Business Officerno datano data0.42%
$ 2.4m
Kathryn McNaughton
Senior Vice President of Portfolio & Program Management3.92yrsno datano data
Holly May
Chief Commercial Officer1yrno datano data

1.2yrs

Average Tenure

56yo

Average Age

Experienced Management: AVRO's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Geoff MacKay
Co- Founder4.92yrsUS$1.82m1.35%
$ 7.9m
Ian Clark
Independent Director2.75yrsUS$142.55k0%
$ 0
Phillip Donenberg
Independent Non-Employee Director2.33yrsUS$145.05k0%
$ 0
Bruce Booth
Independent Chairman of the Board4.67yrsUS$168.80kno data
Philip Vickers
Independent Director1.75yrsUS$344.87k0%
$ 0
Annalisa Jenkins
Independent Director2.5yrsUS$144.55k0%
$ 0
Christopher Paige
Independent Director4.75yrsUS$145.30k0.69%
$ 4.1m

2.8yrs

Average Tenure

59yo

Average Age

Experienced Board: AVRO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.


Top Shareholders

Company Information

AVROBIO, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AVROBIO, Inc.
  • Ticker: AVRO
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$587.997m
  • Shares outstanding: 36.43m
  • Website: https://www.avrobio.com

Number of Employees


Location

  • AVROBIO, Inc.
  • Building 300
  • Suite 201
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVRONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018

Biography

AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies e ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 01:11
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.